Cohen's SAC Capital Accumulates 6.8% Stake in Cardiome Pharma (CRME)
More News related to CRME
- Cardiome Pharma (CRME) Misses Q2 View By 9c
- Cardiome Reports Second Quarter Results
- Cardiome to Release Second Quarter Results and Hold Conference Call
- Unusual 11 Mid-Day Movers: CHIP, BZH, RHD, LCC Higher; BWTR, SIRF, CRME, URRE Lower
- Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
In a 13G filing on Cardiome Pharma (Nasdaq: CRME), Steven Cohen's SAC Capital disclosed a 6.8% stake (4,327,480 shares) in the company. The firm held 36,945 shares of CRME at the quarter ended March 31, 2008.
Cardiome Pharma Corp., through its subsidiaries, operates as a life sciences company that focuses on developing drugs to treat or prevent cardiovascular diseases.
SAC is a multi-strategy, $14 billion hedge fund founded by Steven A. Cohen in 1992.
You can also track all SAC Capital related news at StreetInsider.com here. StreetInsider.com Premium members can get e-mail alerts when there is new SAC Capital news.
Related Categories
13GsStocks Mentioned
-0.18Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
